Reasons for using simetikon Review article
Article Sidebar
Published:
Mar 31, 2017
Keywords:
flatulence, antibiotics, statins, bile acid sequestrants, orlistat, acarbose, metformin, SSRI, acetylsalicylic acid, incretin drugs, sartans, ACE-inhibitors, Ca-blockers
Main Article Content
Abstract
The flatulence is a gastrointestinal tract disorder consisting of gas accumulation. It manifests as discomfort in the abdominal cavity and so called “gas-drop” which significantly reduces the quality of life, and in addition is not socially acceptable. This article presents actual knowledge on drugs, which can cause clinically significant flatulence, and also analyzes the influence of incretin drugs – a new group of antidiabetic drugs – on the function of the gastrointestinal tract. Based on the presented data it seems that in most cases the flatulence is not a clinical problem but rather a problem which negatively affect the life.
Article Details
How to Cite
Krząścik, P., Knypl, K., & Łabuzek, K. (2017). Reasons for using simetikon. Medycyna Faktow (J EBM), 10(1(34), 47-51. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2194
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Herlog G.: Medycyna wewnętrzna. Wydawnictwo Lekarskie PZWL, Warszawa 2007.
2. Jackowska A., Łukaszyk A.: Wzdęcia – mity i fakty. Prz. Gastroenterol. 2008; 3: 243-246.
3. Jarosz M., Dzieniszewski J.: Gazy jelitowe. Porady dla lekarzy i dietetyków. Wydawnictwo Lekarskie PZWL, Warszawa 2003.
4. Pharmindex. Kompendium leków 2015. VIDAL Poland sp. z o.o. Warszawa 2014.
5. Physicians’ desk reference 54 edition. (PDR) Medical economics Company Inc. 2000.
6. Goodman & Gilman‘s: The pharmacological basis of therapeutics 11/Edition. 2006. Wydanie Polskie, Wydawnictwo Czelej Sp. z o.o. 2007.
7. Sweetman S.C.: Martindale: The complete drug reference. 36th edition: CD-ROM, 2009.
8. Kang S., Liu Y., Liu X.B.: Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta- analysis of randomized, controlled trials. Clin. Ther. 2013; 35: 1125-1136.
9. Braamskamp M.J., Kusters D.M., Avis H.J. et al.: Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence. Pediatr. Drugs 2015; 17: 159-166.
10. Muscari A., Puddu G.M., Puddu P.: Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 2002; 97: 115-121.
11. Trindade E., Menon D., Topfer L.A., Coloma C.: Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159: 1245-1252.
12. Focks J.J., Tielemans M.M., van Rossum L.G. et al.: Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin. Neth. Heart J. 2014; 22: 107-112.
13. Gu J., Meng X., Guo Y. et al.: The efficacy and safety of liraglutide added to metformin in patients with diabetes: a metaanalysis of randomized controlled trials. Sci. Rep. 2016; 6: 32714. DOI: 10.1038/srep32714.
14. Smits M.M., Tonneijck L., Muskiet M.H.A. et al.: Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open 2015; 5:e009579. DOI: 10.1136/bmjopen-2015-009579.
15. Russell S.: Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int. J. Clin. Pharm. 2013; 35: 159-172.
16. Blonde L., Montanya E.: Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Diabetes Obes. Metab. 2012; 14(supl. 2): 20-32.
17. Schwartz S., Fonseca V., Berner B.: Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006; 29(4): 759-764.
18. Bronner F.: Mechanisms of intestinal calcium absorption. J. Cell. Biochem. 2003; 88: 387-393.
19. Aljada A., Mousa S.A.: Metformin and neoplasia: implications and indications. Pharmacol. Ther. 2012; 133: 108-115.
20. Gong Z., Aragaki A.K., Chlebowski R.T.: Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: results from the Women’s Health Initiative. Int. J. Cancer 2016; 138(8): 1915-1927.
21. Chen H.P., Shieh J.J., Chang C.C. et al.: Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013; 62(4): 606-615.
22. Sweetman S.C.: Martindale. The Complete Drug Reference, 32nd ed. Pharmaceutical Press 2002.
23. Podlewski J., Chwalibogowska-Podlewska A.: Leki współczesnej terapii. Wydanie XIX. Medical Tribune Polska, Warszawa 2009.
24. Kostowski W., Herman Z.S.: Farmakologia. Podstawy farmakoterapii. Podręcznik dla studentów medycyny i lekarzy. Wydanie III. Wydawnictwo Lekarskie PZWL, Warszawa 2003.
25. Wielosz M.: Farmakologia kliniczna. Wydawnictwo Czelej, Lublin 2001. 26. USP DI 10th Anniversary edition. Drug information for the health care professional. The United States Pharmacopeial Convention Inc. 1990.
2. Jackowska A., Łukaszyk A.: Wzdęcia – mity i fakty. Prz. Gastroenterol. 2008; 3: 243-246.
3. Jarosz M., Dzieniszewski J.: Gazy jelitowe. Porady dla lekarzy i dietetyków. Wydawnictwo Lekarskie PZWL, Warszawa 2003.
4. Pharmindex. Kompendium leków 2015. VIDAL Poland sp. z o.o. Warszawa 2014.
5. Physicians’ desk reference 54 edition. (PDR) Medical economics Company Inc. 2000.
6. Goodman & Gilman‘s: The pharmacological basis of therapeutics 11/Edition. 2006. Wydanie Polskie, Wydawnictwo Czelej Sp. z o.o. 2007.
7. Sweetman S.C.: Martindale: The complete drug reference. 36th edition: CD-ROM, 2009.
8. Kang S., Liu Y., Liu X.B.: Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta- analysis of randomized, controlled trials. Clin. Ther. 2013; 35: 1125-1136.
9. Braamskamp M.J., Kusters D.M., Avis H.J. et al.: Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence. Pediatr. Drugs 2015; 17: 159-166.
10. Muscari A., Puddu G.M., Puddu P.: Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 2002; 97: 115-121.
11. Trindade E., Menon D., Topfer L.A., Coloma C.: Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159: 1245-1252.
12. Focks J.J., Tielemans M.M., van Rossum L.G. et al.: Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin. Neth. Heart J. 2014; 22: 107-112.
13. Gu J., Meng X., Guo Y. et al.: The efficacy and safety of liraglutide added to metformin in patients with diabetes: a metaanalysis of randomized controlled trials. Sci. Rep. 2016; 6: 32714. DOI: 10.1038/srep32714.
14. Smits M.M., Tonneijck L., Muskiet M.H.A. et al.: Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open 2015; 5:e009579. DOI: 10.1136/bmjopen-2015-009579.
15. Russell S.: Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int. J. Clin. Pharm. 2013; 35: 159-172.
16. Blonde L., Montanya E.: Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Diabetes Obes. Metab. 2012; 14(supl. 2): 20-32.
17. Schwartz S., Fonseca V., Berner B.: Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006; 29(4): 759-764.
18. Bronner F.: Mechanisms of intestinal calcium absorption. J. Cell. Biochem. 2003; 88: 387-393.
19. Aljada A., Mousa S.A.: Metformin and neoplasia: implications and indications. Pharmacol. Ther. 2012; 133: 108-115.
20. Gong Z., Aragaki A.K., Chlebowski R.T.: Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: results from the Women’s Health Initiative. Int. J. Cancer 2016; 138(8): 1915-1927.
21. Chen H.P., Shieh J.J., Chang C.C. et al.: Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013; 62(4): 606-615.
22. Sweetman S.C.: Martindale. The Complete Drug Reference, 32nd ed. Pharmaceutical Press 2002.
23. Podlewski J., Chwalibogowska-Podlewska A.: Leki współczesnej terapii. Wydanie XIX. Medical Tribune Polska, Warszawa 2009.
24. Kostowski W., Herman Z.S.: Farmakologia. Podstawy farmakoterapii. Podręcznik dla studentów medycyny i lekarzy. Wydanie III. Wydawnictwo Lekarskie PZWL, Warszawa 2003.
25. Wielosz M.: Farmakologia kliniczna. Wydawnictwo Czelej, Lublin 2001. 26. USP DI 10th Anniversary edition. Drug information for the health care professional. The United States Pharmacopeial Convention Inc. 1990.